Spanish society of medical oncology consensus for the use of haematopoietic colony-stimulating factors in cancer patients

Clinical and Translational Oncology

Volumn 11, Issue 7, 2009, Pages 446-454

  Carrato, Alfredo ^a   Rodríguez, Luis Paz Ares ^b   Lescure, Álvaro Rodríguez ^c   De Tejerina, Ana M Casas Fernández ^a   García, Eduardo Díaz Rubio ^d   Segura, Pedro Pérez ^d   Figueiras, Manuel Constenla ^e   Carbonero, Rocío García ^f   Codina, José Gómez ^g   Hernández, Ana Lluch ^h   Rey, José Pablo Maroto ⁱ   Jiménez, Miguel Martín ^d   Cámara, José Ignacio Mayordomo ^j   Nogueira, José Andrés Moreno ^b   Domínguez, Antonio Rueda ^k  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e HOSPITAL MONTECELO   (Spain)

^f HOSPITAL SEVERO OCHOA   (Spain)

^g HOSPITAL UNIVERSITARIO LA FE   (Spain)

^h HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

ⁱ HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^j HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^k HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

more..

Author keywords

Chemotherapy; Colony stimulating factors; Consensus; Febrile neutropenia; Neutropenia

Indexed keywords

ANTINEOPLASTIC AGENT; COLONY STIMULATING FACTOR;

ARTICLE; CONSENSUS; DRUG COMBINATION; HUMAN; NEOPLASM; NEUTROPENIA; ONCOLOGY; PRACTICE GUIDELINE; SPAIN; URINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONY-STIMULATING FACTORS; CONSENSUS; DRUG THERAPY, COMBINATION; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; NEUTROPENIA; SPAIN;

EID: 73349135001     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-009-0383-1     Document Type: Article

References (61)

1. Kuderer NM, Dale DC, Crawford J et al (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106:2258-2266
2. Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT (2005) Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 103:1916-1924
3. Mayordomo JI, López A, Viñolas N et al on behalf of the ENIA Study Group (2006) Cost of febrile neutropenia management in cancer patients in Spain. J Clin Oncol 24[June 20 Suppl]:6089
4. Lyman GH, Kuderer NM, Djulbegovic B (2002) Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: A meta-analysis. Am J Med 112:406-411
5. Kuderer NM, Dale DC, Crawford J, Lyman GH (2007) Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: A systematic review. J Clin Oncol 25:3158-3167
6. Smith TJ, Khatcheressian J, Lyman GH et al (2006) 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 24:3187-3205
7. Vogel CL, Wojtukiewicz MZ, Carroll RR et al (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: A multicentre, double-blind, placebo controlled phase III study. J Clin Oncol 23:1178-1184
8. Timmer-Bonte JN, de Boo TM, Smit HJ (2005) Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in smallcell lung cancer: A Dutch Randomized Phase III Study. J Clin Oncol 23:7974-7984
9. Crawford J, Althaus B, Armitage J et al (2007) Myeloid growth factors. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 5:188-202
10. Aapro MS, Cameron DA, Pettengell R (2006) EORTC guidelines for the use of granulocytecolony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42:2433-2453
11. Escobar Rodriguez I, Sevilla Azzati E, Rodríguez Sagrero MA et al (1998) Estudio multicéntrico de utilización de factores estimulantes de crecimiento hematopoyético. Farm Hosp 22:109-125
12. Scott SD, Chrischilles EA, Link BK et al (2003) Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin's lymphoma treated with chemotherapy. J Manag Care Pharm 9[2 Suppl]:15-21
13. Almenar D, Mayans J, Juan O et al (2005) Pegfilgrastim and daily granulocyte colony-stimulating factor (G-CSF). Patterns of use and neutropeniarelated outcomes in cancer patients in Spain: Results of the Learn Study. Blood 106[Suppl]: Abstract 4263
14. Lyman GH, Kuderer NM (2003) Epidemiology of febrile neutropenia. Supp Cancer Ther 1:23-25
15. Crawford J, Dale DC, Lyman GH (2004) Chemotherapy-induced neutropenia: Risks, consequences, and new directions for its management. Cancer 100:228-237
16. Greil R, Jost LM (2005) ESMO recommendations for the application of hematopoietic growth factors. ESMO Guidelines Task Force. Ann Oncol 16[Suppl 1]:i80-i82
17. Bunn PA Jr, Crowley J, Kelly K et al (1995) Chemoradiotherapy with or without granulocytemacrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: A prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol 13: 1632-1641
18. Balducci L (2003) New paradigms for treating elderly patients with cancer: The comprehensive geriatric assessment and guidelines for supportive care. J Support Oncol 1[4 Suppl 2]:30-37
19. Balduci L, Carreca I (2002) The role of myelopoietic growth factors in managing cancer in the elderly. Drugs 62:47-63
20. Repetto L (2003) Greater risks of chemotherapy toxicity in elderly patients with cancer J Supp Oncol 4:18-24
21. Lichtman SM, Skirvin JA, Vemulapalli S (2003) Pharmacology of antineoplastic agents in older cancer patients. Crit Rev Oncol Hematol 46:101-114
22. Dale DC (2003) Poor prognosis in elderly patients with cancer: The role of bias and undertreatment. J Support Oncol 1[4 Suppl 2]:11-17
23. Balducci L, Extermann M (2005) Management of cancer in the older person: A practical approach. Oncologist 5:224-237
24. Balducci L, Extermann M (2000) Cancer and aging. An evolving panorama. Hematol Oncol Clin North Am 14:1-16
25. Bower M, McCall-Peat N, Ryan N et al (2004) Protease inhibitors potentiate chemotherapy-induced neutropenia. Blood 104:2943-2946
26. Harbol AW, Liesveld JL, Simpson-Haidaris PJ, Abboud CN (1994) Mechanisms of cytopenia in human immunodeficiency virus infection. Blood Rev 8:241-251
27. Norton L, Simon R (1986) The Norton-Simon hypothesis revisited. Cancer Treat Rep 70:163-169
28. Citron ML, Berry DA, Cirrincione C et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431-1439
29. Pfreundschuh M, Trümper L, Kloess M et al (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL. Blood 104:634-641
30. Pfreundschuh M, Trümper L, Kloess M et al (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: Results of the NHL-B1 trial of the DSHNHL. Blood 104:626-633
31. Pfreundschuh M, Trümper L, Kloess M et al (2005) Six, not eight cycles of bi-weekly CHOP with rituximab (R-CHOP 14) is the preferred treatment for elderly patients with diffuse large-B-cell lymphoma: Results of the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 106:abstract 13
32. Kloess M, Zeynalova S, Trümper L et al (2003) Effects of G-CSF scheduled on leucocyte recovery and infection rate in the CHOP-14 regimen for elderly patients with aggressive lymphoma. Proc Am Soc Clin Oncol 22:597 [abstract 2402]
33. Holmes FA, O'Shaughnessy JA, Vukelja S (2002) Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 20:727-731
34. Siena S, Piccart MJ, Holmes FA et al (2003) A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer. Oncol Rep 10:715-724
35. Wolf M, Bentley M, Marlton P et al (2006) Pegfilgrastim to support CHOP-14 in elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma 47:2344-2350
36. Schneeweiss A, Schuetz F, Rudlowski C et al (2005) Dose-dense primary systemic chemotherapy with gemcitabine plus epirubicin sequentially followed by docetaxel for early breast cancer: Fi nal results of a phase I/II trial. Anticancer Drugs 16:1023-1028
37. Burstein HJ, Parker LM, Keshaviah A et al (2005) Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol 23:8340-8347
38. López A, Fernández de Sevilla A, Castaigne S et al (2004) Pegfilgrastim supports delivery of CHOP-R chemotherapy administered every 14 days: A randomised phase II study. Blood 103:abstract 3311
39. Engert A, Bredenfeld H, Döhner H et al (2006) Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with highrisk Hodgkin's lymphoma: Results of a phase II study. Haematologica 91:546-549
40. Gabrilove JL, Jakubowski A, Scher H et al (1988) Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318:1414-1422
41. Martín M, Lluch A, Seguí MA et al (2006) Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): Impact of adding primary prophylactic granulocytecolony stimulating factor to the TAC regimen. Ann Oncol 17:1205-1212
42. Green MD, Koelbl H, Baselga J et al (2003) International Pegfilgrastim 749 Study Group. A randomized double-blind multicenter phase III study of fi xed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14:29-35
43. Juttner CA, To LB, Haylock DN et al (1985) Circulating autologous stem cells collected in very early remission from acute non-lymphoblastic leukaemia produce prompt but incomplete haemopoietic reconstitution after high dose melphalan or supralethal chemoradiotherapy. Br J Haematol 61:739-745
44. Liu KY, Akashi K, Harada M et al (1993) Kinetics of circulating haematopoietic progenitors during chemotherapy-induced mobilization with or without granulocyte colony-stimulating factor. Br J Haematol 84:31-38
45. Weaver CH, Schulman KA, Wilson-Relyea B et al (2000) Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells. J Clin Oncol 18:43-53
46. Facon T, Harousseau JL, Maloisel F et al (1999) Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: A randomized, controlled trial. Blood 94:1218-1225
47. Bruns I, Steidl U, Kronenwett R et al (2006) A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma. Transfusion 46:180-185
48. Isidori A, Tani M, Bonifazi F et al (2005) Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. Haematologica 90:225-231
49. Prósper F, Solá C, Hornedo J et al (2003) Mobilization of peripheral blood progenitor cells with a combination of cyclophosphamide, r-metHuSCF and filgrastim in patients with breast cancer previously treated with chemotherapy. Leukemia 17:437-441
50. Talcott JA, Siegel RD, Finberg R, Goldman L (1992) Risk assessment in cancer patients with fever and neutropenia: A prospective, two-center validation of a prediction rule. J Clin Oncol 10:316-322
51. Klastersky J, Paesmans M, Rubenstein EB et al (2000) The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038-3051
52. Gerhartz HH, Stern AC, Wolf-Hornung B et al (1993) Intervention treatment of established neutropenia with human recombinant granulocytemacrophage colony-stimulating factor (rhGMCSF) in patients undergoing cancer chemotherapy. Leuk Res 17:175-185
53. Soda H, Oka M, Fukuda M et al (1996) Optimal schedule for administering granulocyte colonystimulating factor in chemotherapy-induced neutropenia in non-small-cell lung cancer. Cancer Chemother Pharmacol 38:9-12
54. Hartmann LC, Tschetter LK, Habermann TM et al (1997) Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med 336:1776-1780
55. Lyman GH, Lyman CG, Sanderson RA, Balducci L (1993) Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst 85:488-493
56. Garcia-Carbonero R, Paz-Ares L (2002) Antibiotics and growth factors in the management of fever and neutropenia in cancer patients. Curr Opin Hematol 9:215-221
57. Berghmans T, Paesmans M, Lafi tte JJ et al (2002) Therapeutic use of granulocyte and granulocytemacrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis. Support Care Cancer 10:181-188
58. Clark OA, Lyman G, Castro AA et al (2003) Colony stimulating factors for chemotherapy induced febrile neutropenia. Cochrane Database Syst Rev (3):CD003039
59. Clark OA, Lyman GH, Castro AA et al (2005) Colony-stimulating factors for chemotherapy-induced febrile neutropenia: A meta-analysis of randomized controlled trials. J Clin Oncol 23:4198-4214
60. Biesma B, de Vries EG, Willemse PH (1990) Efficacy and tolerability of recombinant human granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related leukopenia and fever. Eur J Cancer 26:932-936
61. Maher DW, Lieschke GJ, Green M (1994) Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Ann Intern Med 121:492-501